FDA warns Maple Organics over OTC drug CGMP failures, unapproved new drugs, and misbranding.
What happened
FDA reviewed records Everlaan Organics submitted after its September 4, 2024 request under section 704(a)(4) and found significant CGMP violations at its Surrey, British Columbia facility. The records did not show finished-product release testing, incoming component identity testing, an adequate stability program, complete batch records, or effective quality-unit oversight. FDA also reviewed product labels and website claims and found unapproved new-drug and misbranding violations for four OTC products.
What FDA found
The firm did not show it tested each finished OTC drug batch for identity and strength before release.
21 CFR 211.165(a)The firm did not show it ran at least one identity test on each incoming component lot.
21 CFR 211.84(d)(1)The firm's stability program was inadequate because it covered only accelerated testing and used a supplement reference, not a drug reference.
21 CFR 211.166(a)Batch production and control records lacked key manufacturing details such as equipment, in-process controls, yield, and container closures.
21 CFR 211.188(b)The quality unit did not effectively approve or reject components and products, review batch records, oversee stability, or perform process validation.
21 CFR 211.22(a)Joint Pain Relief and Muscle Pain Relief were sold as unapproved new drugs, and the four products had misleading FDA-approval/validation claims or missing directions for use.
FD&C Act 505(a), 502(a), 502(f)(1), 502(ee)
What FDA wants
FDA tells the firm to correct the violations promptly and to provide the requested plans, specifications, records, testing summaries, and assessments. It also warns that FDA may withhold approval of new applications listing the firm until the violations are fully addressed.
Who should pay attention
- U.S. importers and distributors of Maple Organics OTC drugs
- retailers or brands that sell these OTC products
- contract manufacturers and testing labs used by such firms
This is a summary. Read the original letter on fda.gov.